Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc(LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab
-
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe
-
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen
ATLAS study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen
-
Iain Mackay appointed GSK Chief Financial Officer
GSK today announced that Iain Mackay has been appointed GSK’s next CFO.
-
CHMP recommend Nucala (mepolizumab) for the treatment of severe eosinophilic asthma paediatric patients in Europe
GSK announced, EMA's CHMP is recommending Nucala as an add-on treatment for severe refractory eosinophilic asthma in paediatric patients.
-
GSK reports on outcome of the FDA Advisory Committee on mepolizumab for the treatment of COPD patients on maximum inhaled therapy
Advisory Committee provide non-binding recommendation for consideration by the FDA
-
GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
Multi-year collaboration to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes
-
GSK delivers improvements in sales, margins and cash flow in Q2 2018
Total EPS 9.0p, >100% AER, >100% CER; Adjusted EPS 28.1p, +3% AER, +10% CER
-
GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK
GlaxoSmithKline plc and Adaptimmune Therapeutics plc, announced the transition of the development programme for GSK3377794 to GSK.
-
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.
-
ViiV Healthcare presents phase III data at AIDS 2018 from landmark GEMINI studies showing two-drug regimen of dolutegravir and lamivudine has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no emergence of resistance
GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads.
-
US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
-
ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018
ViiV, specialist HIV company will be presenting over 20 abstracts, including GEMINI 1 & 2 trials, at the AIDS 2018 in Amsterdam.
-
US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria
There is substantial evidence of the effectiveness and adequate evidence of the safety of single-dose tafenoquine
-
James Ford appointed GSK General Counsel
James Ford, currently SVP and General Counsel for Global Pharma, will succeed Dan Troy as General Counsel, GSK.
-
Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
GSK today announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof.
-
GSK announce...
GSK announce...
-
Infants may now be protected against Meningitis B with fewer doses, adding flexibility to vaccination schedules
Healthcare professionals now have more options to help protect infants from invasive meningococcal disease (IMD) caused by serogroup B
-
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
GEMINI 1&2 studies meet primary endpoint, demonstrating similar efficacy of two-drug regimen compared to standard three-drug regimen
-
GSK presents new results showing low rates of organ damage with long term use of Benlysta
Results showing low rates of organ damage progression in patients with active systemic lupus erythematosus treated with Benlysta